Clinical trials: Essential,Hypertension
Essential Hypertension
Comparing Safety and Efficacy of Amlodipine Verses S Amlodipine in Patients With Essential Hypertension
As a third-generation dihydropyridine calcium channel blocker (CCB), Amlodipine is mainly used in a single therapy or combined therapy for hypertension or angina.
- Trial name
- NCT04554303
- Testing
- S-amlodipine 2.5mg, Amlodipine 5mg
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Primary Aldosteronism, Essential Hypertension
The Plasma Metabolomics Profiling of Primary Aldosteronism
Primary aldosteronism (PA), characterized by overt renin-independent aldosterone production, is the most common form endocrine hypertension.
- Conditions
- Primary Aldosteronism, Essential Hypertension, Idiopathic Aldosteronism, Aldosterone-producing Adenoma
- Trial name
- NCT06500000
- Testing
- liquid chromatography-mass spectrometry (LC/MS)
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Third Military Medical University
Hypertension
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
- Trial name
- NCT00696384
- Testing
- Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
- Where
- 45 sites in United States, Argentina and 1 more
- Volunteers
- 418 people
- Sponsor
- Takeda
Hypertension
A Safety and Tolerability Study of the Combination of Aliskiren/Valsartan in Patients With High Blood Pressure, Followed by Long-term Safety and Tolerability of Aliskiren, Valsartan and Hydrochlorothiazide.
Assessment of the long-term safety and tolerability of the combination of aliskiren and valsartan (300 mg/ 320 mg) in patients with high blood pressure,followed by assessment of long-term safety and tolerability of the…
- Trial name
- NCT00386607
- Testing
- Aliskiren, Valsartan, Hydrochlorothiazide (HCTZ)
- Where
- 4 sites in United States, Canada and 2 more
- Volunteers
- 601 people
- Sponsor
- Novartis
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-3 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT05199129
- Testing
- HCP1904-3, RLD2001-1
- Where
- South Korea
- Volunteers
- 166 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Essential Hypertension
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
This study assessed the efficacy of LCZ696 in Japanese patients with essential hypertension
- Trial name
- NCT01599104
- Testing
- LCZ696, Olmesartan
- Where
- 61 sites in Japan
- Volunteers
- 1,161 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study
This is a multi-center, randomized, double-blind, 6 x 3 cross-over study. All patients who meet the entry criteria will be required to stop taking any other anti-hypertensive agents than Adalat CR (controlled release), if taken…
- Trial name
- NCT00768560
- Testing
- Nifedipine (Adalat CR, BAYA1040) 80mg OD, Nifedipine (Adalat CR, BAYA1040) 40mg BID, Nifedipine (Adalat CR, BAYA1040) 40mg OD
- Where
- 3 sites in Japan
- Volunteers
- 35 people
- Sponsor
- Bayer
Hypertension
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
- Trial name
- NCT00344110
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 768 people
- Sponsor
- Novartis
Essential Hypertension
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
The purpose of this study is to evaluate the safety by assessing all serious and non-serious adverse events (AEs), irrespective of relatedness or expectedness, as well as other safety parameters including laboratory values…
- Trial name
- NCT04470830
- Where
- South Korea
- Volunteers
- 718 people
- Sponsor
- Celltrion Pharm, Inc.
Essential Hypertension, Diabetes Mellitus
Effects Of Losartan On Myocardial Structure In Diabetic Hypertensive Patients With Left Ventricular
The anthypertensive treatment with Losartan may have benefits beyond blood pressure reduction on myocardial structure and function in hypertensive diabetic patients.
- Trial name
- NCT00659451
- Testing
- Losartan, Amlodipine
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Pavia
Hypertension
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension
The objective of this PMS study was to monitor and assess the safety of Micardis tablets in patients with hypertension over a period of 6 years
- Trial name
- NCT02245464
- Testing
- Telmisartan
- Volunteers
- 13,066 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension.
Inflammatory Response to Salt in Essential Hypertension
Salt is a main environmental risk factor involved in atherosclerotic complications and in the high risk of a variety of cardiovascular (CV) diseases including hypertension, left ventricular hypertrophy (LVH), chronic kidney…
- Trial name
- NCT01665534
- Testing
- High salt intake
- Volunteers
- 32 people
- Sponsor
- Carmine Zoccali
Hypertension
The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy
A multi-center, randomized, double-blind, phase IV clinical trial to compare the efficacy and safety of OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg in patients with essential hypertension uncontrolled with…
- Trial name
- NCT02433119
- Testing
- OROSARTAN® 5/160mg, CODIOVAN® 160/12.5mg
- Where
- South Korea
- Volunteers
- 238 people
- Sponsor
- Dong-A ST Co., Ltd.
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Evaluation of Cerebral Small Vessel Disease in Patient With Primary Aldosteronism
Hypertension is known to be the major risk factor for stroke. The most common cause of secondary hypertension, primary aldosteronism (PA), is characterized by the excessive secretion of aldosterone and is related to hypertension…
- Trial name
- NCT03821571
- Testing
- Brain MRI
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Essential Hypertension
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension
- Trial name
- NCT00654875
- Testing
- Aliskiren
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 328 people
- Sponsor
- Novartis
Hypertension
Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate of efficacy and safety of amlodipine plus losartan and amlodipine alone in patients with essential hypertension inadequately controlled on amlodipine monotherapy.
- Trial name
- NCT00940667
- Testing
- Amlodipine plus Losartan, Amlodipine
- Where
- South Korea
- Volunteers
- 185 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Essential Hypertension
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure.
- Trial name
- NCT00425373
- Testing
- Valsartan + amlodipine 40/2.5 mg, Valsartan + amlodipine 40/5 mg, Valsartan + amlodipine 80/2.5 mg
- Where
- Japan
- Volunteers
- 1,474 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Blood Pressure
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE-HTN-II)
This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.
- Conditions
- Hypertension, Blood Pressure, Cardiovascular Diseases
- Trial name
- NCT06018493
- Testing
- focused power ultrasound mediate inferior perirenal adipose tissue modification
- Where
- 4 sites in China
- Volunteers
- 79 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hypertension
Essential Oil of Eucalyptus Effect on Cardiovascular Responses
The essential eucalyptus oil has therapeutic potential in the cardiovascular system, with possibilities of acting on the autonomic tonus and reduction of cardiovascular overload.
- Trial name
- NCT02656004
- Testing
- Essential Eucalyptus Oil, Control Session
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do vale do São Francisco